2024
P170 Ixekizumab significantly improved quality of life and joint pain in patients with psoriatic arthritis, nail disease and distal interphalangeal joint involvement from SPIRIT-H2H
Ritchlin C, Kavanaugh A, Kristensen L, Merola J, Strober B, Lisse J, Bolce R, Sapin C, Pustizzi J, McGonagle D. P170 Ixekizumab significantly improved quality of life and joint pain in patients with psoriatic arthritis, nail disease and distal interphalangeal joint involvement from SPIRIT-H2H. Rheumatology 2024, 63: keae163.209. DOI: 10.1093/rheumatology/keae163.209.Peer-Reviewed Original ResearchHealth Assessment Questionnaire-Disability IndexDermatology Life Quality IndexSF-36Quality of lifeJoint painMental and Physical Component Summary scoresQoL measuresConsulting feesUCB PharmaPhysical component summary scoreHealth care providersComponent summary scoresSF-36 MCSSF-36 PCSIXE-treated patientsClinically important improvementNail Psoriasis Severity IndexADA-treated patientsDistal interphalangeal jointDistal interphalangeal joint involvementDermatology Life Quality Index scoresStatistically significant improvementVisual analogue scaleCare providersJoint involvementAssociation of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis
McGonagle D, Kavanaugh A, McInnes I, Kristensen L, Merola J, Strober B, Bolce R, Lisse J, Pustizzi J, Sapin C, Ritchlin C. Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis. Rheumatology 2024, keae060. PMID: 38341669, DOI: 10.1093/rheumatology/keae060.Peer-Reviewed Original ResearchNail psoriasisJoint involvementPsoriatic arthritisJoint tendernessTargeting IL-17ADistal interphalangeal joint involvementPost hoc analysisPost-baseline assessmentSPIRIT-H2HInhibitor adalimumabIL-17AAdalimumabStudy cohortTNF-aDrug classesMusculoskeletal outcomesPsoriasisPatientsHoc analysisDistal interphalangealIxekizumabSynovio-entheseal complexWeeksAdjacent nailPSA
2023
POS1526 TREATMENT EFFECTS OF IXEKIZUMAB AND ADALIMUMAB AT THE INDIVIDUAL DIGIT LEVEL WITH NAIL AND DISTAL INTERPHALANGEAL JOINT INVOLVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS
Mcgonagle D, Kavanaugh A, Mcinnes I, Kristensen L, Merola J, Strober B, Bolce R, Lisse J, Pustizzi J, Sapin C, Ritchlin C. POS1526 TREATMENT EFFECTS OF IXEKIZUMAB AND ADALIMUMAB AT THE INDIVIDUAL DIGIT LEVEL WITH NAIL AND DISTAL INTERPHALANGEAL JOINT INVOLVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS. 2023, 1124-1125. DOI: 10.1136/annrheumdis-2023-eular.5.Peer-Reviewed Original ResearchDistal interphalangeal joint involvementInterphalangeal joint involvementPsoriatic arthritisJoint involvementTreatment effectsIxekizumabAdalimumabArthritisPatientsP169 Treatment effects of ixekizumab and adalimumab at the individual digit level with nail and distal interphalangeal joint involvement in patients with psoriatic arthritis
McGonagle D, Kavanaugh A, McInnes I, Kristensen L, Merola J, Strober B, Lisse J, Pustizzi J, Sapin C, Bolce R, Ritchlin C. P169 Treatment effects of ixekizumab and adalimumab at the individual digit level with nail and distal interphalangeal joint involvement in patients with psoriatic arthritis. Rheumatology 2023, 62 DOI: 10.1093/rheumatology/kead104.210.Peer-Reviewed Original ResearchNail Psoriasis Severity IndexProportion of patientsPsoriatic arthritisWeek 24Nail diseaseNail involvementDIP involvementSanofi GenzymeWeek 52Total scoreEli LillyExact testNail bedUCB PharmaDistal interphalangeal (DIP) joint diseaseDistal interphalangeal joint involvementDifferent biological therapiesInterphalangeal joint involvementNail matrix involvementPsoriatic nail diseasePost-baseline assessmentPsoriasis Severity IndexNHS Greater GlasgowFisher's exact testTotal maximum score